Scholar Rock announced that it has completed enrollment of the SAPPHIRE Phase 3 trial evaluating the safety and efficacy of apitegromab in nonambulatory patients with Types 2 and 3 spinal muscular atrophy (SMA) who are receiving SMN therapy (either nusinersen or risdiplam). The company also announced that it plans to present core data from its Phase 2 TOPAZ trial extension period evaluating patient outcomes in SMA after 36 months of treatment with apitegromab. Efficacy and safety data at 36 months, and an analysis of patient-reported outcome measures such as fatigue, mobility, and activities of daily living, will be presented during two poster presentations at the 28th Annual Congress of the World Muscle Society from October 3 - 7 in Charleston, South Carolina, USA.